Synthetically-evolved and engineered Nanobodies selective for Cb isoforms of PKA
对 PKA Cb 亚型具有选择性的合成进化和工程纳米抗体
基本信息
- 批准号:10525796
- 负责人:
- 金额:$ 43.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAnimalsAntigensBacteriaBindingBiological AssayBrainCatalytic DomainCellsCollaborationsCommunitiesComplexCoupledCrystallizationCyclic AMP-Dependent Protein KinasesEngineeringExonsFamilyGoalsHumanImageIn VitroIncentivesIndividualInflammationJournalsKineticsKnowledgeLabelLaboratoriesLate Onset Alzheimer DiseaseLengthLinkLymphoid TissueMapsMediatingMetabolic DiseasesMethodsMitochondriaMolecular EvolutionMusN-terminalNeurodegenerative DisordersNeuronsPeptide FragmentsPeptidesPhosphotransferasesProtein AnalysisProtein FamilyProtein IsoformsProtein KinaseProtein SubunitsProteinsPublishingRNARNA SplicingReagentResearchResearch PersonnelRetinaRoleSamplingScientistScreening procedureSignal TransductionSpecificityStructureT-LymphocyteTailTechnologyTissue ModelTissuesVariantWestern BlottingWorkalpha helixbasediagnostic toolearly detection biomarkersearly onsetextracellularhigh riskhuman imaginghuman tissuemitochondrial dysfunctionmouse modelnanobodiesneuropathologyprotein complexrapid techniqueretinal imagingretinal neuronscreeningtoolvirtual
项目摘要
ABSTRACT. Our collaboration builds on the protein kinase expertise of the Taylor lab and the expertise of the
Chang lab to isolate Synthetically-evolved and engineered Nanobodies (SENs). Our goal is to isolate SENs
that will discriminate between the isoforms of the catalytic (C) subunits of cAMP-dependent protein kinase
(PKA). This builds on the realization that >50% of PKA signaling in the brain is mediated by C subunits.
Although the C subunit of PKA was the second to be discovered, the first to be sequenced, and the first to be
crystallized, virtually nothing is known about the C proteins, which represent a family of proteins that differ
only in their N-terminal sequence encoded for by Exon 1. The C3/4 isoforms are expressed exclusively in
brain while C2 is expressed in lymphoid tissues and T cells. Using the retina as a “Window into the Brain”
Taylor showed that C is highly expressed in these terminally differentiated neurons and that it localizes
differently from C, which supports the functional non-redundancy of these isoforms. The surprising discovery
that C, but not C, RII, or RII, localizes to mitochondria adds further credence to the importance of C and
its link to neurodegenerative diseases. To validate the hypothesis that imaging of the retina could serve as a
window into the more complex signaling in brain and to determine if PKA signaling changes as a function of the
onset and progression of AD, Taylor, in collaboration with the Alzheimer Disease Research Center at UCSD
(UCSD ADRC) Neuropathology Core and Robert Rissman who directs this core is now comparing AD brains
from individuals with mild and advanced AD. The preliminary results, coupled with imaging of pTau, a hallmark
of advanced AD, confirm the hypothesis and highlight the importance of having tools that will discriminate
between the various C isoforms. To achieve this essential next step we turned to the newly developed SENS
technology. Using C-subunit proteins, purified in the Taylor lab, the Chang lab will fluorescently tag the proteins
and then select for SENs that will discriminate between the different C-subunit isoforms. Initially they will focus
on C4/C4ab as these, based on RNA scope, appeared to be the best candidates for association with
mitochondria, and C2 which is expressed in T cells and has the potential to serve as a Biomarker for early
onset PD. In Aim I Taylor will express C-subunit isoforms as well as peptide fragments that correspond to the
N-terminal tails of each subunit. In Aim II Chang will fluorescently tag these proteins and through multiple
rounds of screening will isolate selective high affinity SENs. These SENs will be analyzed for their ability to
detect specific isoforms by Western blots and by imaging in both human and mouse tissues. Inhibition of
kinase activity will also be assessed. A long-term goal will be to crystallize SENs: C-subunit complexes.
Because this toolbox of reagents can be widely used by both clinicians and basic scientists, this is a high
risk/high return opportunity that can have a high impact. Our work will be published quickly in open access
journals and the SENS will be freely available to all researchers.
抽象的。我们的合作基于泰勒实验室的蛋白激酶专业知识和专业知识
Chang Lab以分离合成进化和工程的纳米体(SENS)。我们的目标是隔离感官
这将区分cAMP依赖性蛋白激酶的催化(C)亚基的同工型
(PKA)。这是基于以下意识到,大脑中> 50%的PKA信号传导是由C亚基介导的。
尽管PKA的C亚基是第二个被发现的,但第一个被测序,第一个是
结晶,几乎没有关于C蛋白的了解,它代表了一个不同的蛋白质家族
仅以外显子1编码的N末端序列。C3/4同工型仅在
脑C2在淋巴组织和T细胞中表达。使用视网膜作为“进入大脑的窗户”
泰勒(Taylor)表明,C在这些末端分化的神经元中高度表达,并且它本地化
与C不同,它支持这些同工型的功能性非差额。令人惊讶的发现
那个c,c,rii或rii本地化到线粒体的本地化,这进一步增加了C的重要性和
它与神经退行性疾病的联系。为了验证视网膜成像可以用作的假设
进入大脑中更复杂的信号的窗口,并确定PKA信号是否随着函数的变化而变化
泰勒(Taylor)的AD发作和进展与UCSD的阿尔茨海默氏病研究中心合作
(UCSD ADRC)导演此核心的神经病理学核心和罗伯特·里斯曼(Robert Rissman)现在正在比较广告大脑
来自有轻度和高级广告的人。初步结果,再加上PTAU的成像,标志
高级AD,确认假设并突出具有歧视工具的重要性
在各种C同工型之间。为了实现这一基本下一步,我们转向了新开发的Sens
技术。 Chang Lab使用C纯化的C-亚基蛋白,将荧光标记蛋白
然后选择将区分不同C-亚基同工型的SENS。最初他们会集中精力
基于RNA范围,在C4/C4AB上似乎是与
线粒体和C2在T细胞中表达,具有早期生物标志物的潜力
发作PD。在目标上,泰勒将表达C-亚基同工型以及对应于
每个亚基的N末端尾巴。在Aim II中,Chang将荧光标记这些蛋白质,并通过多个
筛选的综合将隔离选择性高亲和力SENS。这些感官将因其能力而分析
通过蛋白质印迹检测特定的同工型,并在人体和小鼠组织中进行成像。抑制
激酶活性也将进行评估。一个长期目标是结晶sens:c-subunit络合物。
因为这种试剂工具箱可以被临床医生和基本科学家广泛使用,所以这是一个很高的
风险/高回报机会可能会产生很大的影响。我们的工作将在公开访问中迅速发布
所有研究人员将免费提供期刊和SENS。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEOFFREY A CHANG其他文献
GEOFFREY A CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEOFFREY A CHANG', 18)}}的其他基金
Biosynthesis of marine terpenoid natural products
海洋萜类天然产物的生物合成
- 批准号:
10737210 - 财政年份:2023
- 资助金额:
$ 43.45万 - 项目类别:
Nanobody inhibitors of proton-sensing G protein-coupled receptors
质子感应 G 蛋白偶联受体的纳米抗体抑制剂
- 批准号:
10216432 - 财政年份:2021
- 资助金额:
$ 43.45万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10380036 - 财政年份:2021
- 资助金额:
$ 43.45万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10184466 - 财政年份:2021
- 资助金额:
$ 43.45万 - 项目类别:
Development of low-cost, field-ready nanobodies against snake venom
开发低成本、可现场使用的抗蛇毒纳米抗体
- 批准号:
10255596 - 财政年份:2021
- 资助金额:
$ 43.45万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10594973 - 财政年份:2021
- 资助金额:
$ 43.45万 - 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
- 批准号:
9893680 - 财政年份:2019
- 资助金额:
$ 43.45万 - 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
- 批准号:
10018872 - 财政年份:2019
- 资助金额:
$ 43.45万 - 项目类别:
Identity, mechanisms and early life impacts of transporter interfering compounds
转运蛋白干扰化合物的特性、机制和早期生命影响
- 批准号:
10179393 - 财政年份:2018
- 资助金额:
$ 43.45万 - 项目类别:
Identity, mechanisms and early life impacts of transporter interfering compounds
转运蛋白干扰化合物的特性、机制和早期生命影响
- 批准号:
10424481 - 财政年份:2018
- 资助金额:
$ 43.45万 - 项目类别:
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 43.45万 - 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
- 批准号:
10660332 - 财政年份:2023
- 资助金额:
$ 43.45万 - 项目类别:
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
阿尔茨海默病和唐氏综合症中 APP 拷贝数变异对 Reelin 表达和功能的影响
- 批准号:
10760161 - 财政年份:2023
- 资助金额:
$ 43.45万 - 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
- 批准号:
10576674 - 财政年份:2023
- 资助金额:
$ 43.45万 - 项目类别:
Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease
诊断适体试剂用于开发针对临床前、轻度和中度阿尔茨海默病的多分析物血液检测
- 批准号:
10597840 - 财政年份:2023
- 资助金额:
$ 43.45万 - 项目类别: